Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So Hai KANY HAS A COVID 19 test kit that is rated very high by the WHO
Nice close, let's see if the day traders drag it down tomorrow.
Good morning Pumping Pete.
No news and no funding. All it will take is some bad news and I believe that I could not sell faster then it will be dropping. Just my opinion based on my investment.
I'm getting ready to sell and move on, good luck to all. The only one who will make money on this BIO is KW.
KW doesn't care one way of the other. It's the same old story the rich can never have enough money. The will make money off the backs of people and never loss a second of sleep. All you can hope for is KW has one decent bone in his body.
Nothing but good news today, PMCB is moving in the right direction. Hopefully we will see some upwards movement,
That's right we are all still here and not leaving with out big money.
Patients I agree 100%, BINGO and Elvis has left the building. LOL
All I'm offering is an example of why at this level the stock comes down after moving up on the trading day.
Day traders; This strategy involves profiting from a stock's daily volatility. This is done by attempting to buy at the low of the day and sell at the high of the day. Here the price target is simply at the next sign of a reversal, using the same patterns as above. Followers of PMCB, watch the stocks movements during the course of a trading day
Day traders sell today buy tomorrow. No need here for concern as soon as the price goes up they will move on.
The only people selling are day traders. PMCB has a 1.5% spread +\-. This is a day traders wet dream.
Now where having fun, everyone is agreeing to disagree ending with LOL. We have not control over whether PMCB is successful or not.
I have not been posting but have been following posts on this board. I'm new here, but having been through another long term OTC and its members messages board,this board is like a dejavu for me. It's true what they said people are the some. The point I'm making is facts, figures or opinions by posters Are conversational only unless they are facts based on verifiable informations. Believe this or not, positive or negative posts effect the price of this stock by swaying new and old investors to sell or be turned off and not buy. If your post is your opinion let readers know, if it's a fact gave them the source. Just my opinion.
This board will make an old man older. An opinion is just that sometimes it's based on facts, gut feelings or just plain old BS conversation. When people ran around like there hair is on fire because of an opinion by anyone is LOL TIME FOR ME. I don't know anyone on this board but I do hope all of you hit it big for yourself and your family. That being said, I will no longer be posting.
In my opinion taking all factors into consideration, the technology, IND filing, FDA interest in fast tracking, trials beginning soon, coupled with ETF, 50 cents to a buck. Once the trials begin increases to $1.50 to $2.00. I have no idea how ETF will effect price. Once word gets out the FDA will announce results rapid trading to $8 to $15. If approved $30 plus rapid trading till things settle could be higher or lower. Trading will stabilize. Movement will depend on further product development or buy out. This is my opinion based on my prior success with HGSI and having observed other Penny stocks success. Not factor in buy out or unforeseen events, trial failures and financial factors. Take this for what it is one person opinion.
3:45 PM EST March 1, 2017
President Donald Trump used his first address to a joint session of Congress on Tuesday to, among other things, promise to "slash the restraints" put on drug development by the Food and Drug Administration and across the government so the "slow and burdensome (drug) approval process" doesn't hinder medical advances.
To illustrate his point, he invited "miracles" like Megan Crowley to attend the speech.
Crowley is a 20-year-old sophomore at the University of Notre Dame who wasn't expected to live past age 5. She has Pompe disease, a serious and rare inherited disorder that leads to severe muscle weakness and heart problems. It is typically fatal. The disease had no pharmaceuticaltreatment until her father founded a company to develop an enzyme replacement therapy that would help save her life.
Trump's message was consistent with conservatives' interest in deregulation and in keeping with what he said on the campaign trail, when he said he would like to "speed the approval of life-saving medications" and pledged that he would be "cutting the red tape at the FDA."
In January, he told a meeting of pharmaceutical company executives in the Oval Office, "we have to get rid of a tremendous number of regulations." He promised that his administration will be "streamlining the process so that from your standpoint, so that when you have a drug, you can actually get it approved — if it works — instead of waiting for many, many years."
But it may not be that simple. Here's what to know about the FDA's drug-approval process and how cutting red tape could lead to cures.
What does the FDA do when it comes to drug approval?
The FDA was set up to protect Americans from unsafe and ineffective drugs.
Before you can buy a prescription drug at your local pharmacy, it must meet strict standards set out by the FDA. The agency will decide, based on all the data it gets from a company, that the drug is safe and that there is proof it will have the effect the company says it has.
If it isn't safe or effective, it won't go to market.
How does approval work?
The company runs experiments on a drug in a lab and on animals and then tests it on a small number of humans to get the dosage right.
Once the drug is determined to be safe, it can be tested on larger and larger groups of humans to prove that it does what the company claims.
Once the company thinks it has enough data to support its claims, it will submit research to the FDA for review. The FDA will evaluate the research and decide to accept or reject it.
How long does the testing process take?
It depends on the complexity of the research. More than two-thirds of new drugs are approved on the basis of studies lasting six months or less.
How long does it take to develop a drug?
On average, it takes 12 years to go from the research lab to the patient. But the drug that makes it to a patient is an exception. Only five in 5,000 of the drugs that are in preclinical testing make it to human drug trials, and only one in five is ever approved for human use.
How long does the review take?
The agency has a 10-month window to do a standard review for drugs that offer, at best, minor improvements over existing market therapies.
Is there a way to move a drug along faster?
In 1992, the Prescription Drug User Fee Act created a system called "priority review," a label given to drugs that show major advances in treatment or provide medical help where there was none.
The agency has a goal of completing those reviews in six months.
Has the review process gotten faster or slower over time?
Congress and the FDA have created mechanisms to make this process go a lot faster in the past couple of decades.
There has been a steady push from politicians and the industry to move the process along. During the AIDS crisis of the late 1980s and 1990s, that push took on a new urgency when a disproportionately large group of young people died while waiting for government approval of drugs that had showed great promise.
After enormous pressure from politicians and AIDS activists, in 1988, the FDA formalized its "fast track" designation, which would approve drugs that could treat a life-threatening or severely debilitating illness after earlier-stage tests.
In 1992, the FDA created the "accelerated approval" process, which allows drugs to go ahead with even earlier-stage data if they would be used to treat a life-threatening or serious illness. That year, the FDA also created the "priority review" system.
The 1983 law called the Orphan Drug Act gives tax breaks and an exclusive market for a period to drugs that treat patients with a disease that may be too rare for researchers to find enough subjects for typical large randomized trials.
Drug companies would often not develop drugs for these markets because there may not have been enough incentive to invest in a product that would be used by so few people.
Crowley's father was able to set up his company and make the drug that saved her under the authority of this act.
Has this faster process inspired innovation?
That's complicated.
Since the FDA created this faster process, an increasing number of companies have used it to get their drugs to market, but there aren't necessarily an abundance of "miracles" and breakthrough drugs. In fact, a 2015 independent analysis of drugs approved during this faster processing time found that the trend"is being driven by drugs that are not first in class and thus potentially are less innovative."
What drugs have benefited from the sped-up process?
Imatinib, a drug used to treat chronic myelogenous leukemia, benefited from all four programs created to speed the drug approval process and got through in a mere 2½ months of FDA review, one study showed.
Have there been any problems related to a quick approval process?
Gemtuzumab, a drug that went through the accelerated approval process and was approved in 2000 to treat myeloid leukemia, a bone marrow cancer, was voluntarily withdrawn in 2010. The additional studies required by the FDA after expedited approval contradicted earlier research, finding that people who took it had no improvement and that there were a greater number of deaths among patients who took it. The drug was also associated with a potentially fatal liver condition.
Studies also show that some drugs approved using this quicker process had a number of significant adverse events and required an additional warning labels called black-box warnings.
That's what happened with the drug rosiglitazone. Eight years after it was approved, the maker had to put black-box labels because research showed that taking it raised the risk of congestive heart failure and death from cardiovascular causes.
© 2017 Cable News Network, Inc. A Time Warner Company. All Rights Reserved.
Anyone on this board could be a insider, pumper or selling short,That's why everyone should do their own homework. Day traders buy and sell stocks that they afford to buy thousands of for a couple of hundred dollars, than turn than over for a few bucks. Day traders usually have a set dollar amount they want too make per day. They are a fact of life with penny stocks. As soon as the stock no longer suit there purpose they move on to another stock because they have no real interest or position. I could care less, but if someone wanted to know wait till PMCB breaks out, and see who is still on this board. Just my opinion.
ROCMAN1, did you figure in MMJ ETF?
Once the IND is announced it will spike higher than what I have seen posted here. At that point it will be out of reach for a lot of people who want to buy large amounts. Unless there are some set backs PMCB will be off and ranning and you may not see anything under 50 cents or even as high as a buck. Just my opinion, but make a note for yourself, you heard it first from BIOBEAR
Your right Pete buy in bunches, don't wake the sleeping dog
In at 11.5 21,500 shares will buy more Monday? Iooked for a CO that has something so unique like an approach to treating life threatening diseases, cell in a box, coupled with some prior success and FDA looking to push this technology. Lastly a great group of medical and scientific people, bingo. One more thing, FAITH. Two months in. Pete you sound like a straight person best of luck to you. Spend your wealth wisely opportunities let this come once in a life time.
Everything with PMCB feel just like when I hit it big time back a few years ago with HGSI, in at &1.36 and sold at $26.52 a share. All non believers search it. One more time, go PMCB .
If you have done your research than you have everything you need to know to get involved with PMCB. The only thing left is to buy in or not and to keep up with the news on progress. Post on this site people here are knowledgeable and straight up. Seat back relax, this CO has to much potential, enjoy the ride.
This is my first post. Searching for a new Bio CO to invest in when I found this one. It had the one thing That I looking for a cutting edge product that could change how we treat life threatening Cancer. and other non-threatening conditions. This CO meets and exceeds all my requirements. This is a high risk investment that shouldn't be taken for granted, invest only what you can afford to lose. But my gut tells me this one is a grand slam. I'm all in.